Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of oral COL-144 for acute migraine treatment
2008-005010-43Phase 2Completed
- Sponsor
- CoLucid Pharmaceuticals
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in migraine comparing COL-144 oral dose-ranging with Placebo (2 arms). Primary endpoint: Headache response at two hours. Started May 2009; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on 2008-005010-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005010-43.